In The Spotlight
From media giants to exclusive industry publications, Humacyte stays in the news.





December 1, 2020
Humacyte’s Bioengineered Blood Vessel Implanted by Clinicians at Walter Reed to Restore Blood Circulation to Retired Military Veteran’s Leg


October 20, 2020
Humacyte and CNTR Team on MTEC Grant to Study the Evidence on Repair of Vascular Trauma



May 22, 2019
Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient

May 10, 2019
Bioengineered blood vessels could replace vasculature damaged by renal failure, CVD

April 9, 2019
Artificial blood vessels that come to life could improve medical care. Here’s why


March 29, 2019
Study finds Humacyte acellular vessels repopulated to create living vessels

March 29, 2019
Scientists Make Blood Vessels From Cadaver Tissues And Bring Them to Life in Patients

Awards & Acknowledgments
Diversity Journal Women Worth Watching
Humacyte’s Sabrina Osborne, Vice President of Human Resources, was named a 2019 winner for Diversity Journal’s women Worth Watching list.
Triangle Business Journal Life Sciences Awards
Humacyte recognized for best late-stage product development company’ category.
Triangle Business Journal 2018 Innovation Awards
Humacyte President and Chief Executive Officer was selected to Triangle Business Journal’s 2018 Innovation Awards List.
Humacyte was named as a finalist in the Strategic Investment Category to the SEBIO 2018 Awards List
Humacyte was recognized for securing a $150M strategic investment from Fresenius Medical, the world’s largest dialysis company, to commercialize HUMACYL for dialysis applications.
Triangle Business Journal 2018 C-Suite Awards List
Humacyte Chief Regulatory Office Bill Tente was selected to Triangle Business Journal’s 2018 C-Suite List.
Diversity Journal Women’s Worth Watching
Gretchen Smith, Humacyte’s Executive Director, Manufacturing was named a 2018 winner for Diversity Journal’s Women Worth Watching list.

Humacyte Founder Shannon Dahl’s, Ph.D. Named to the 2018 PharmaVoice100 List Awards Finalist
Dr. Dahl was recognized by PharmaVoice for breaking bioengineering ground, with regenerative medicine.
Humacyte’s Theodore Lithgow, Chief Operations Officer, was recognized in the 2017 Best in Biz awards under the Executive of the Year
Humacyte’s Theodore Lithgow, Chief Operations Officer, was recognized in the 2017 Best in Biz awards under the Executive of the Year
Medical Design & Outsourcing: Humacyte’s Carrie Cox named to 9 Women Medtech Leaders You Need to Know list
Medical Design & Outsourcing: Humacyte’s Carrie Cox named to 9 Women Medtech Leaders You Need to Know list

Humacyte Founder Laura Niklason, M.D., Ph.D. Named to the 2017 PharmaVoice100 List Awards Finalist
Dr. Niklason was recognized by PharmaVoice for her contributions to the advancement of regenerative medicine, in creating investigational human acellular vessels.

Humacyte Founder Laura Niklason, M.D., Ph.D. Inducted into the Women in Technology (WITI) Hall of Fame
Dr. Niklason was inducted into the Women in Technology Fall of Fame for her groundbreaking research in regenerative strategies for cardiovascular and lung tissues.

Humacyte’s Heather Prichard, Ph.D., named as a 2017 award winner for Diversity Journal’s Women Worth Watching in STEM
Senior Vice President, Product Development Dr. Heather Prichard was named as a 2017 award winner for Diversity Journal’s Women Worth Watching in STEM in recognition of her work to develop technologies for improving medical treatment for a variety of diseases.

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum
Humacyte was selected as a 2017 Technology Pioneer by the World Economic Forum for the potential to significantly impact business and society through new technologies in regenerative medicine.

Humacyte’s Juliana Blum and Jenny Jackson Named to Profiles in Diversity Journal’s 2017 Women Worth Watching List
Dr. Juliana Blum, Co-Founder and Vice-President, Business Operations & Tissue Services and Jenny Jackson, Associate Director of Reimbursement for Humacyte, were recognized to Diversity Journal’s Women Worth Watching in 2017 award for their personal and professional contributions to advancing gender diversity.

Humacyte Founder Dr. Laura Niklason and Humacyte CEO Carrie Cox Named to Becker’s Hospital Review List of 110 Women in Medtech to Know
Humacyte Founder, Dr. Niklason and Humacyte CEO, Carrie Cox were both recognized to Becker’s Hospital Review, “110 Women in Medtech to Know”

Humacyte Founder Laura Niklason, M.D., Ph.D. Recognized on Fortune Magazine’s List of Leaders Transforming Health and Medicine
Dr. Niklason was recognized to Fortune Magazine’s prestigious List of Leaders Transforming Health and Medicine, for her contributions to the advancement of regenerative medicine, in creating investigational human acellular vessels.

Humacyte Founder Dr. Laura Niklason, M.D., Ph.D. awarded with a 2016 LAS Alumni Achievement Award
Dr. Laura Niklason received a LAS Alumni Achievement Award from the University of Illinois College of Liberal Arts & Sciences for groundbreaking work in tissue engineering in 2016.

Humacyte named 2016 Fierce Innovation Awards finalist
Humacyte was named to Fierce Innovation’s Awards Life Sciences Edition in 2016 for creating HUMACYL

Humacyte named to FierceBiotech’s Top 15 Private Companies in the Medical Devices Space for 2016
Humacyte was named to FierceBiotech’s Top 15 Private Companies in Medical Devices for the potential to significantly impact business and society through new technologies in regenerative medicine.

WSJ Includes Humacyl as one of “Six New Medical Technologies Worth Watching”
Humacyte was highlighted as a potential breakthrough for patients undergoing hemodialysis.

Humacyte makes CNBC Disruptor 50 List
Humacyte was named to CNBC’s prestigious Disrupt 50 List for the progress HUMACYL has made since Humacyte’s founding.

Humacyte Chief Medical Officer Jeffrey H. Lawson M.D., Ph.D. Elected to Fellowship in the American Surgical Association
Humacyte’s Chief Medical Officer, Dr. Jeffery H. Lawson was elected as a Fellow to the prominent American Surgical Association for his experience and leadership as a medical professional.

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Medicine
Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies and Founder of Humacyte, has been elected to the prestigious National Academy of Medicine (NAM). NAM is an independent organization of eminent professionals from diverse fields including health and medicine; the natural, social, and behavioral sciences, and beyond.

North Carolina Excellence Award
Humacyte, an innovator in biotechnology and regenerative medicine, announced today that the Company has been awarded the 2015 North Carolina Excellence Award by the US Commerce & Trade Research Institute (USCTRI), a leading research authority that evaluates and recognizes businesses and organizations that have made a significant contribution in enterprise and entrepreneurial growth.

Excellence in Commerce Award
The Small Business Institute for Excellence in Commerce (SBIEC) recognizes Humacyte with the 2013 North Carolina Excellence Award for continued advancement of business leadership and high regard for upholding business ethics and company values among its peers.

Top 10 Women in Biotech
Fierce Biotech names Carrie Cox as one of the “Top 10 Women in Biotech”

Fast Company Top 50 World’s Most Innovative Companies
Fast Company names Humacyte as one of the “Top 50 World’s Most Innovative Companies”

Popular Mechanics Breakthrough Innovation of 2011
Popular Mechanics recognizes Humacyte investigational bioengineered blood vessel technology as a “Breakthrough Innovation of 2011.” This technology is under clinical study by Humacyte, and Humacyte plans to seek FDA approval of the technology.

Frost & Sullivan New Product Innovation
Humacyte receives Frost & Sullivan Award for New Product Innovation